Thursday, December 9, 2010

12/10 RegenMD

     
    RegenMD    
   
U of A gets $26.5M stem cell research facility
December 9, 2010 at 5:39 PM
 
"This is going to be the future of regenerative medicine, and if we don't get into it now we're going to be way behind all the other universities," said ...
See all stories on this topic »
   
   
JAPAN'S OLYMPUS TO BUY REGENERATIVE MEDICINE OPS IN U.S.
December 9, 2010 at 1:37 PM
 
(TSE:7733) said Tuesday it has agreed with Stryker Corp. to purchase a portion of the US medical equipment maker's regenerative-medicine-related assets for ...
See all stories on this topic »
   
   
The Odd Business of Electing a New CIRM Chair, Plus Klein Says No to Salary
December 9, 2010 at 11:12 AM
 
   
   
More Than You Want to Know About Serial Meetings
December 9, 2010 at 11:08 AM
 
   
   
BioTime Asia, Limited and Shanghai Genext Medical Technology Co., Ltd. Sign ...
December 9, 2010 at 10:05 AM
 
BioTime's technologies in regenerative medicine are based on the power of human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells to ...
See all stories on this topic »
   
   
HAMILTON THORNE LAUNCHES GROUNDBREAKING STILETTO™ LASER SYSTEM FOR STEM CELL ...
December 9, 2010 at 8:58 AM
 
"The new Stiletto™ laser addresses a significant challenge in the regenerative medicine, developmental biology and advanced cell biology markets where ...
See all stories on this topic »
   
   
Harvard Bioscience Files 2 Patents In Regenerative Medicine Field - Quick Facts
December 9, 2010 at 8:58 AM
 
Harvard Bioscience is collaborating with leading academics in the field of regenerative medicine to develop its regenerative medicine products. by RTT Staff ...
See all stories on this topic »
   
   
Endothelial progenitor cells correlate with lesion volume and growth in acute stroke.
December 9, 2010 at 4:23 AM
 
Related Articles

Endothelial progenitor cells correlate with lesion volume and growth in acute stroke.

Neurology. 2010 Dec 7;75(23):2059-62

Authors: Bogoslovsky T, Chaudhry A, Latour L, Maric D, Luby M, Spatz M, Frank J, Warach S

OBJECTIVES: Circulating endothelial progenitor cells (EPC) are markers of vascular injury and their numbers decrease in acute stroke. However, the relation of EPC levels to stroke severity has not been quantified. MRI measurements of lesion volume provide an objective method for stroke severity assessment and outcome prediction. This cross-sectional study aims to determine whether EPC are correlated with lesion volume at baseline, lesion growth, and final lesion volume. METHODS: Seventeen patients (median age 63 years, NIH Stroke Scale score 7) were selected from 175 patients with imaging-confirmed acute ischemic stroke. EPC were quantified by flow cytometry using CD34, CD133, and VEGFR2 surface markers. Brain MRI was performed at baseline and at days 1 and 5 after the stroke onset. Stroke lesion volumes were quantified. RESULTS: Larger lesion volumes measured on diffusion-weighted images (DWI) at baseline were associated with low EPC levels, while smaller lesion volumes and less lesion growth were linked with high levels of EPC subsets (CD34+CD133+, CD133+VEGFR2+, and CD34+ CD133+VEGFR2+). Similar results were observed with DWI lesion volumes and EPC (CD34+CD133+) on day 1. Lesion growth volume, represented as a difference between final lesion volume and baseline DWI, was larger in patients with lower day 1 EPC (CD133+VEGFR2+). After adjustments for age and admission glucose (model 1), mean arterial pressure and white blood cells (model 2), INR and hematocrit (model 3), the CD34+CD133+ subset remained predictive of baseline and day 1 lesion volumes, while CD133+VEGFR2+ predicted baseline lesion volume and growth of lesion volume. CONCLUSIONS: Higher EPC levels were indicative of smaller volumes of acute lesion, final lesion, and lesion growth, and may serve as markers of acute phase stroke severity. However, a larger prospective study is needed to confirm our findings.

PMID: 21135380 [PubMed - in process]

   
   
BestOfOTC.com Notable Stocks to Watch at ACTC, MSLP, SAVW, TXHG, GHNA, RNRG
December 9, 2010 at 4:15 AM
 
... company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. ...
See all stories on this topic »
   
   
No Real Problem with Canadians as CIRM Chair
December 9, 2010 at 1:36 AM
 
   
   
Nano way to scientific breakthrough
December 9, 2010 at 12:44 AM
 
"Tissue engineering and MRI are some of the important applications to alleviate human suffering, giving hope to scores of people," he said. ...
See all stories on this topic »
   
     
 
This email was sent to regenmd@gmail.com.
Delivered by Feed My Inbox
PO Box 682532 Franklin, TN 37068
Account Login
Unsubscribe Here Feed My Inbox
 
     

No comments: